DBV Technologies S.A. (DBVT)
| Market Cap | 969.96M |
| Revenue (ttm) | 5.74M |
| Net Income (ttm) | -167.45M |
| Shares Out | 295.91M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,757 |
| Open | 15.68 |
| Previous Close | 16.02 |
| Day's Range | 15.62 - 16.48 |
| 52-Week Range | 8.51 - 26.19 |
| Beta | -0.22 |
| Analysts | Buy |
| Price Target | 39.73 (+148.16%) |
| Earnings Date | Jul 28, 2026 |
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ... [Read more]
Financial Performance
In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price target is $39.73, which is an increase of 148.16% from the latest price.
News
DBV Technologies S.A.: DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT - CUSIP: 23...
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
Châtillon, France, June 23, 2026 DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306...
DBV Technologies S.A.: DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq S...
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock...
DBV Technologies S.A.: DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study,...
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
Châtillon, France, June 8, 2026 DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 In the Phase 3 VITESSE study, VI...
DBV Technologies S.A.: DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Ma...
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Châtillon, France, June 5, 2026 DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market...
DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financier...
DBV Technologies S.A.: DBV Technologies Announces the Results of its 2026 Combined General Meeting
Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV - ISIN: FR...
DBV Technologies Announces the Results of its 2026 Combined General Meeting
Châtillon, France, June 3, 2026 DBV Technologies Announces the Results of its 2026 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR001...
DBV Technologies S.A.: DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy Th...
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The ...
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The st...
DBV Technologies Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
A novel skin-based immunotherapy for pediatric peanut allergy is nearing BLA filing, with a clear regulatory path and plans for pipeline expansion into other food allergies. Market entry will focus on allergists and parental engagement, with future growth driven by platform efficiencies and new indications.
Combined General Meeting of June 3, 2026
Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV...
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...
DBV Technologies Proxy statement: Proxy filing
DBV Technologies filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
DBV Technologies Slides: Corporate presentation
DBV Technologies has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
DBV Technologies Proxy statement: Proxy filing
DBV Technologies filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
DBV Technologies price target raised to $55 from $47 at Citizens
Citizens raised the firm’s price target on DBV Technologies (DBVT) to $55 from $47 and keeps an Outperform rating on the shares. DBV Technologies is advancing toward commercialization of Viaskin…
DBV Technologies reports Q1 EPS (11c), consensus (12c)
“The entire DBV team has been operating with exceptional focus and rigor as we progress towards significant milestones in the coming months, including the upcoming Biologics License Application (BLA) ...
DBV Technologies Reports First Quarter 2026 Financial Results
Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the seco...
DBV Technologies Earnings release: Q1 2026
DBV Technologies released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
DBV Technologies Quarterly report: Q1 2026
DBV Technologies has published its Q1 2026 quarterly earnings report on April 30, 2026.